News Releases

A seasoned executive with deep knowledge and experience of biotechnology and healthcare operations.

Vyriad, Inc. today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, LLC with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment roster.

An interview with Dr. Stephen Russell discussing the development of an oral vaccine from Vyriad.

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2.

Harry is a highly regarded Life Sciences Investor, previously served as CIO and Treasurer to Mayo Clinic.

Measuring COVID-19 antibodies with a high-throughput clinical assay

Clinical validation of high throughput assay that provides numeric results (titer) of neutralizing antibodies. Former COVID-19 patients, in a small preliminary sample set, saw marked decline in neutralizing antibodies within six months. Assay shows no guarantee that severe disease results in higher levels of antibody protection.

High-throughput clinical assay detects and quantifies SARS-CoV-2 neutralizing antibodies

High-throughput clinical assay detects, quantifies SARS-CoV-2-neutralizing antibodies. Imanis Life Sciences is an affiliate of Vyriad Inc.

Study combines Vyriad’s oncolytic virus Voyager-V1 and the PD-1 inhibitor Libtayo® (cemiplimab) in skin, lung, liver and uterine cancer

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments. Vyriad to receive upfront payment and equity investment from Regeneron.

Custom buildout to be financed by recently completed $9 million secured convertible note funding

Sanford Health first in nation to launch Phase I of the Vyriad viro-immunotherapy trial

Combination of Tessa’s Virus Specific T cell (VST) platform and Vyriad’s oncolytic viruses are highly synergistic and have the potential to effectively target a broad range of hard-to-treat solid tumors

Bexon Clinical Consulting to provide Vyriad with clinical operations support

Company secures equity position in StingInn, LLC